ONBI — One Bio Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 27.4% | ||
Return on Equity | 19.8% | ||
Operating Margin | 27.5% |
Financial Summary
Year End 31st Dec | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.21 | 0.14 | 10.4 | 22.07 | 52.3 | n/a | n/a | 298.68% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | -4.18 | +44.81 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
ONE Bio, Corp. (ONE), formerly ONE Holdings, Corp. is a bio-engineering company that utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. Its key products include Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. Its operations are divided into two principal complementary business units that focus on producing chemical and herbal extracts (CHE business unit) and organic products utilizing green processes (OP business unit).
Directors
- Michael Weingarten CHM (56)
- Marius Silvasan CEO (38)
- Cris Neely CFO (54)
- Min Zhao CEX (42)
- Qingsheng Fan IND (48)
- James Fernandes IND (40)
- Frank Klees IND
- Jan Koe IND (66)
- John Perkins IND (46)
- Last Annual
- December 31st, 2010
- Last Interim
- September 30th, 2011
- Incorporated
- June 30th, 2000
- Public Since
- March 31st, 2008
- No. of Employees
- 358
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 8,470,682

- Address
- 500 S Australian Ave., Suite 600, WEST PALM BEACH, 33401
- Web
- https://one.bio/
- Phone
- +1 3053288662
- Auditors
- Jewett, Schwartz, Wolfe & Associates
Similar to ONBI
Adia Nutrition
Pink Sheets on Nasdaq
African Agriculture Holdings
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
FAQ
As of Today at 22:26 UTC, shares in One Bio are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in One Bio last closed at $0.00 and the price had moved by -40% over the past 365 days. In terms of relative price strength the One Bio share price has underperformed the S&P500 Index by -43.94% over the past year.
There is no consensus recommendation for this security.
Find out moreOne Bio does not currently pay a dividend.
One Bio does not currently pay a dividend.
One Bio does not currently pay a dividend.
To buy shares in One Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in One Bio had a market capitalisation of .
Here are the trading details for One Bio:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ONBI
Based on an overall assessment of its quality, value and momentum One Bio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like One Bio. Over the past six months, its share price has underperformed the S&P500 Index by -37.89%.
As of the last closing price of $0.00, shares in One Bio were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The One Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
One Bio's management team is headed by:
- Michael Weingarten - CHM
- Marius Silvasan - CEO
- Cris Neely - CFO
- Min Zhao - CEX
- Qingsheng Fan - IND
- James Fernandes - IND
- Frank Klees - IND
- Jan Koe - IND
- John Perkins - IND